Total Payments
$353,813
2024 Payments
$45,175
Companies
7
Transactions
190
Medicare Patients
7,918
Medicare Billing
$526,710
Payment Breakdown by Category
Research$347,675 (98.3%)
Other$4,800 (1.4%)
Food & Beverage$737.67 (0.2%)
Travel$559.42 (0.2%)
Education$40.79 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $347,675 | 159 | 98.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,800 | 1 | 1.4% |
| Food and Beverage | $737.67 | 26 | 0.2% |
| Travel and Lodging | $559.42 | 2 | 0.2% |
| Education | $40.79 | 2 | 0.0% |
Payments by Type
Research
$347,675
159 transactions
General
$6,138
31 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk AS | $348,482 | 165 | $0 (2024) |
| PFIZER INC. | $4,800 | 1 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $255.01 | 16 | $0 (2020) |
| BIOTRONIK INC. | $187.44 | 4 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $48.60 | 2 | $0 (2023) |
| Relypsa, Inc. | $21.30 | 1 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.53 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $45,175 | 13 | Novo Nordisk AS ($40,375) |
| 2023 | $86,799 | 32 | Novo Nordisk AS ($86,775) |
| 2022 | $89,599 | 38 | Novo Nordisk AS ($89,575) |
| 2021 | $71,975 | 34 | Novo Nordisk AS ($71,975) |
| 2020 | $48,023 | 32 | Novo Nordisk AS ($48,000) |
| 2019 | $7,652 | 16 | Novo Nordisk AS ($7,575) |
| 2018 | $4,311 | 14 | Novo Nordisk AS ($4,207) |
| 2017 | $277.96 | 11 | BIOTRONIK INC. ($187.44) |
All Payment Transactions
190 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | PFIZER INC. | VYNDAMAX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/22/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $6,250.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 10/22/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $5,300.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 08/07/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $4,450.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 07/03/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $3,650.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 05/23/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $3,800.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 05/23/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $2,825.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 04/04/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $3,650.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 02/29/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $2,075.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 02/07/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $3,300.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 02/07/2024 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $500.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 01/19/2024 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $1,825.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 01/05/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $2,750.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 12/08/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $1,050.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 11/28/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,625.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 11/07/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $500.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 10/19/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $3,125.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 10/10/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $250.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 10/03/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $250.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 08/10/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $6,300.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 08/10/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $750.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 07/26/2023 | Novo Nordisk AS | Wegovy (Drug) | — | Cash or cash equivalent | $2,675.00 | Research |
| Study: EX9536-4388 • Category: Obesity | ||||||
| 07/20/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $4,025.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 07/18/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $2,350.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 07/11/2023 | Novo Nordisk AS | Wegovy (Drug) | — | Cash or cash equivalent | $7,900.00 | Research |
| Study: EX9536-4388 • Category: Obesity | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EX9536-4388 | Novo Nordisk AS | $176,750 | 53 |
| EX9924-4473 | Novo Nordisk AS | $136,250 | 55 |
| NN9535-4321 | Novo Nordisk AS | $32,675 | 45 |
| NN9536-4373 | Novo Nordisk AS | $850.00 | 2 |
| NN9536-4374 | Novo Nordisk AS | $625.00 | 3 |
| NN9536-4376 | Novo Nordisk AS | $525.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,887 | 2,466 | $819,457 | $128,395 |
| 2022 | 14 | 2,178 | 2,731 | $957,541 | $148,203 |
| 2021 | 12 | 2,246 | 2,686 | $907,131 | $141,351 |
| 2020 | 12 | 1,607 | 2,041 | $711,608 | $108,761 |
Total Patients
7,918
Total Services
9,924
Medicare Billing
$526,710
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 360 | 705 | $387,750 | $76,103 | 19.6% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 201 | 201 | $123,213 | $12,520 | 10.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 535 | 758 | $109,910 | $9,790 | 8.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 61 | 61 | $60,817 | $8,853 | 14.6% |
| 78803 | Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | Facility | 2023 | 145 | 146 | $43,070 | $6,424 | 14.9% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 234 | 234 | $28,080 | $3,973 | 14.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 43 | 50 | $18,750 | $3,400 | 18.1% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 256 | 257 | $20,303 | $2,924 | 14.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 12 | $8,940 | $1,946 | 21.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $10,640 | $1,586 | 14.9% |
| 78451 | Nuclear medicine study of heart muscle at rest and with stress and spect | Facility | 2023 | 11 | 12 | $6,180 | $625.90 | 10.1% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 11 | 11 | $1,804 | $252.67 | 14.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 349 | 664 | $365,200 | $71,433 | 19.6% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2022 | 302 | 302 | $185,126 | $19,928 | 10.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 73 | 73 | $72,781 | $10,394 | 14.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 422 | 588 | $85,260 | $7,508 | 8.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 86 | 97 | $36,375 | $7,356 | 20.2% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2022 | 341 | 342 | $41,040 | $6,401 | 15.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 37 | 92 | $47,748 | $6,155 | 12.9% |
| 78803 | Nuclear medicine study, 1 area with spect | Facility | 2022 | 126 | 126 | $37,170 | $5,543 | 14.9% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2022 | 365 | 366 | $28,914 | $4,550 | 15.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 24 | 24 | $13,440 | $2,515 | 18.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $16,992 | $2,241 | 13.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 19 | $13,585 | $1,783 | 13.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 13 | $9,100 | $1,587 | 17.4% |
About Dr. Lawrence Phillips, M.D
Dr. Lawrence Phillips, M.D is a Cardiovascular Disease healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/06/2008. The National Provider Identifier (NPI) number assigned to this provider is 1447420369.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lawrence Phillips, M.D has received a total of $353,813 in payments from pharmaceutical and medical device companies, with $45,175 received in 2024. These payments were reported across 190 transactions from 7 companies. The most common payment nature is "" ($347,675).
As a Medicare-enrolled provider, Phillips has provided services to 7,918 Medicare beneficiaries, totaling 9,924 services with total Medicare billing of $526,710. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location New York, NY
- Active Since 03/06/2008
- Last Updated 03/23/2021
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1447420369
Products in Payments
- Wegovy (Drug) $133,550
- Rybelsus (Drug) $101,025
- RYBELSUS (Drug) $34,700
- Ozempic (Drug) $32,675
- VYNDAMAX (Drug) $4,800
- XARELTO (Drug) $255.01
- LEQVIO (Drug) $24.34
- ENTRESTO (Drug) $24.26
- Veltassa (Drug) $21.30
- PRADAXA (Drug) $18.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in New York
Dr. Roger Hajjar, Md, MD
Cardiovascular Disease — Payments: $5.2M
Cardiovascular Disease $5.2M
Dr. Jacob Koruth, M.d, M.D
Cardiovascular Disease — Payments: $3.2M
Cardiovascular Disease $3.2M
Dr. Martin Leon, M.d, M.D
Cardiovascular Disease — Payments: $2.7M
Cardiovascular Disease $2.7M
Dr. Gregg Stone, M.d, M.D
Cardiovascular Disease — Payments: $2.2M
Cardiovascular Disease $2.2M
Adam Rosenbluth, Md, MD
Cardiovascular Disease — Payments: $1.5M
Cardiovascular Disease $1.5M
Dr. Deepak Bhatt, Md, MD
Cardiovascular Disease — Payments: $1.4M
Cardiovascular Disease $1.4M